deKernion JB - Search Results

1

The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.

Figlin RA, Abi-Aad AS, Belldegrun A, deKernion JB. Figlin RA, et al. Among authors: dekernion jb. Semin Oncol. 1991 Oct;18(5 Suppl 7):102-7. Semin Oncol. 1991. PMID: 1719641 Review.

2

Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.

Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Zisman A, et al. Among authors: dekernion jb. J Urol. 2003 Mar;169(3):909-16. doi: 10.1097/01.ju.0000045706.35470.1e. J Urol. 2003. PMID: 12576811

3

Mathematical model to predict individual survival for patients with renal cell carcinoma.

Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS. Zisman A, et al. Among authors: dekernion jb. J Clin Oncol. 2002 Mar 1;20(5):1368-74. doi: 10.1200/JCO.2002.20.5.1368. J Clin Oncol. 2002. PMID: 11870181

4

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.

Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS. Zisman A, et al. Among authors: dekernion jb. J Clin Oncol. 2002 Dec 1;20(23):4559-66. doi: 10.1200/JCO.2002.05.111. J Clin Oncol. 2002. PMID: 12454113

5

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.

Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Figlin RA, et al. J Clin Oncol. 1992 Mar;10(3):414-21. doi: 10.1200/JCO.1992.10.3.414. J Clin Oncol. 1992. PMID: 1482425 Clinical Trial.

6

Immunotherapy for renal cell carcinoma.

Belldegrun A, Figlin R, Danella J, deKernion J. Belldegrun A, et al. Semin Urol. 1992 Feb;10(1):23-7. Semin Urol. 1992. PMID: 1565900 Review.

7

Interferon in renal cell carcinoma. The UCLA experience.

Sarna G, Figlin R, de Kernion J. Sarna G, et al. Cancer. 1987 Feb 1;59(3 Suppl):610-2. doi: 10.1002/1097-0142(19870201)59:3+<610::aid-cncr2820591306>3.0.co;2-f. Cancer. 1987. PMID: 3542184 Clinical Trial.

8

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.

Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, deKernion J, Belldegrun A. Figlin RA, et al. J Urol. 1997 Sep;158(3 Pt 1):740-5. doi: 10.1097/00005392-199709000-00012. J Urol. 1997. PMID: 9258071 Clinical Trial.

9

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, deKernion J, Belldegrun A. Figlin R, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S92-7. Cancer J Sci Am. 1997. PMID: 9457402 Clinical Trial.

10

Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.

Belldegrun A, Tso CL, Kaboo R, Pang S, Pierce W, deKernion JB, Figlin R. Belldegrun A, et al. Among authors: dekernion jb. J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):149-61. doi: 10.1097/00002371-199603000-00008. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8732698 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

252 results

Search Page

Filters